文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

评估无培养靶向下一代测序诊断耐药结核病:两种端到端商业工作流程的多中心临床研究

Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows.
PubMed 文献 · Lancet Infect Dis · 2024-10-29

在格鲁吉亚、印度和南非三个国家的参考实验室开展前瞻性横断面多中心临床评估,共纳入720例分子学确诊的肺结核且存在利福平耐药风险的成人患者。两种靶向下一代测序(tNGS)工作流程对利福平和异烟肼的灵敏度和特异度均超过95%,对氟喹诺酮类灵敏度约≥94%,对二线注射剂灵敏度80%。无培养tNGS可从临床沉淀样本中准确检测和表征结核分枝杆菌耐药性。

要点

  • 两种tNGS工作流程对利福平和异烟肼的灵敏度和特异度均超过95%。
  • 对氟喹诺酮类灵敏度约≥94%,对二线注射剂灵敏度80%。
  • 可检测贝达喹啉和利奈唑胺耐药相关突变,但当前剂型对利奈唑胺灵敏度≤50%。

核心结论

  • 无培养tNGS可从结核分枝杆菌临床沉淀样本中提供准确的测序结果,用于检测和表征耐药性,实现及时、全面的耐药结核病分析。

研究设计与样本

  • 前瞻性、横断面、多中心临床评估,在格鲁吉亚、印度和南非三个国家的参考实验室评估两种靶向下一代测序(tNGS)工作流程(GenoScreen Deeplex Myc-TB和Oxford Nanopore Technologies [ONT] Tuberculosis Drug Resistance Test)的诊断准确性和检测失败率。
  • 纳入标准为年龄18岁及以上、分子学确诊的肺结核、且存在利福平耐药风险的患者;2021年4月1日至2022年6月30日期间邀请832人参与,最终分析纳入720人(格鲁吉亚212人、印度376人、南非132人)。

主要发现

  • 在720份临床沉淀样本中,GenoScreen和ONT tNGS工作流程分别有658份(91%)和684份(95%)产生完整或部分结果;在616份涂片阳性样本中,分别有593份(96%)和603份(98%)产生tNGS序列数据。
  • 与复合参考标准(表型药物敏感性试验和全基因组测序)相比,两种工作流程对利福平和异烟肼的灵敏度和特异度均超过95%,对氟喹诺酮类灵敏度约≥94%,对二线注射剂灵敏度80%。
  • 这些检测还可检测与贝达喹啉和利奈唑胺等关键新药和再利用药物耐药相关的突变,目前市场上任何其他WHO推荐的快速诊断方法均无法检测这些突变。
  • 当前剂型的检测对利奈唑胺的灵敏度低(≤50%),需要更多关于耐药相关突变的研究。

局限性

  • 当前剂型的检测对利奈唑胺的灵敏度低(≤50%),需要更多关于耐药相关突变的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug-resistant tuberculosis remains a major obstacle in ending the global tuberculosis epidemic. Deployment of molecular tools for comprehensive drug resistance profiling is imperative for successful detection and characterisation of tuberculosis drug resistance. We aimed to assess the diagnostic accuracy of a new class of molecular diagnostics for drug-resistant tuberculosis. METHODS: We conducted a prospective, cross-sectional, multicentre clinical evaluation of the performance of two targeted next-generation sequencing (tNGS) assays for drug-resistant tuberculosis at reference laboratories in three countries (Georgia, India, and South Africa) to assess diagnostic accuracy and index test failure rates. Eligible participants were aged 18 years or older, with molecularly confirmed pulmonary tuberculosis, and at risk for rifampicin-resistant tuberculosis. Sensitivity and specificity for both tNGS index tests (GenoScreen Deeplex Myc-TB and Oxford Nanopore Technologies [ONT] Tuberculosis Drug Resistance Test) were calculated for rifampicin, isoniazid, fluoroquinolones (moxifloxacin, levofloxacin), second line-injectables (amikacin, kanamycin, capreomycin), pyrazinamide, bedaquiline, linezolid, clofazimine, ethambutol, and streptomycin against a composite reference standard of phenotypic drug susceptibility testing and whole-genome sequencing. FINDINGS: Between April 1, 2021, and June 30, 2022, 832 individuals were invited to participate in the study, of whom 720 were included in the final analysis (212, 376, and 132 participants in Georgia, India, and South Africa, respectively). Of 720 clinical sediment samples evaluated, 658 (91%) and 684 (95%) produced complete or partial results on the GenoScreen and ONT tNGS workflows, respectively, with 593 (96%) and 603 (98%) of 616 smear-positive samples producing tNGS sequence data. Both workflows had sensitivities and specificities of more than 95% for rifampicin and isoniazid, and high accuracy for fluoroquinolones (sensitivity approximately ≥94%) and second line-injectables (sensitivity 80%) compared with the composite reference standard. Importantly, these assays also detected mutations associated with resistance to critical new and repurposed drugs (bedaquiline, linezolid) not currently detectable by any other WHO-recommended rapid diagnostics on the market. We note that the current format of assays have low sensitivity (≤50%) for linezolid and more work on mutations associated with drug resistance is needed. INTERPRETATION: This multicentre evaluation demonstrates that culture-free tNGS can provide accurate sequencing results for detection and characterisation of drug resistance from Mycobacterium tuberculosis clinical sediment samples for timely, comprehensive profiling of drug-resistant tuberculosis. FUNDING: Unitaid.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Colman RE, Seifert M, De la Rossa A, et al. Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows. Lancet Infect Dis. 2024. PMID: 39486428. doi:10.1016/S1473-3099(24)00586-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。